Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Janice Chen, Christopher L. Brooks, Peter McDonald, Jonathan D. Schwartz, Keiichi Sakakibara, Naoya Saito...Takuji Sato, Takumi Kawabe, Eric Keith Rowinsky | ||||||||||||
Title | Preclinical activity of SL-801, a reversible inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) in solid and hematologic cancers | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.e13543 | ||||||||||||
Abstract Text | Journal of Clinical Oncology 33, no. 15_suppl |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SL-801 | SL 801 | SL-801 is a small molecule inhibitor of XPO1, which prevents substrates from binding to XPO1, thereby disrupting the nuclear export of proteins, and thus, may lead to inhibition of tumor growth (Journal of Clinical Oncology 33, no. 15_suppl). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|